76,473 results match your criteria Acute Myelogenous Leukemia


Cancer risk in oil refinery workers: a pooled mortality study in Italy.

Med Lav 2019 Feb 22;110(1):3-10. Epub 2019 Feb 22.

Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano.

Background: Oil refinery workers are exposed to several well-established carcinogens and working in this type of industry has been classified by IARC as probable carcinogen to humans (Group 2A).

Objectives: To examine the mortality experience of workers employed in four Italian oil refineries.

Methods: The cohort included 5112 male workers ever employed between 1949 and 2011. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23749/mdl.v110i1.7842DOI Listing
February 2019

Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study.

Int J Lab Hematol 2019 Feb 22. Epub 2019 Feb 22.

Department of Hematology, School of Medicine, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China.

Introduction: AML with inv(3)(q21.3q26.2) or t(3;3)(q21. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijlh.12987DOI Listing
February 2019

Establishment and molecular characterization of decitabine-resistant K562 cells.

J Cell Mol Med 2019 Feb 22. Epub 2019 Feb 22.

Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China.

The clinical activity of decitabine (5-aza-2-deoxycytidine, DAC), a hypomethylating agent, has been demonstrated in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. However, secondary resistance to this agent often occurs during treatment and leads to treatment failure. It is important to clarify the mechanisms underlying the resistance for improving the efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcmm.14221DOI Listing
February 2019

Role of physical function in predicting short-term treatment outcome in Egyptian acute myeloid leukemia patients: a single center experience.

Hematol Transfus Cell Ther 2019 Jan-Mar;41(1):17-24. Epub 2018 Jun 14.

Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt.

Background: Acute myeloid leukemia (AML) is a potentially fatal hematological disease. Along with disease-related factors, patient-related factors, in particular age, are a strong predictor of outcome that influence treatment decisions. Many acute myeloid leukemia risk stratification models have been developed to predict the outcome of intensive chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.htct.2018.05.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371199PMC

TP53 immunohistochemistry correlates mutation status and clearance in decitabine-treated patients with myeloid malignancies.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

Dept. of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.205302DOI Listing
February 2019

miR-101 suppresses the development of MLL-rearranged acute myeloid leukemia.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

Children Cancer Institute, University of New South Wales, Sydney, Australia;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.209437DOI Listing
February 2019

RUNX1 inhibits proliferation and induces apoptosis of t(8;21) leukemia cells via KLF4 mediated transactivation of P57.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and PUMC

RUNX1 is a key transcription factor in hematopoiesis and its disruption is one of the most common aberrations in acute myeloid leukemia. RUNX1 alterations affect its DNA binding capacity and transcriptional activities, leading to the deregulation of transcriptional targets and abnormality in proliferation and differentiation of myeloid cells. Identification of RUNX1 target genes and elucidation of their biological functions are of great importance to find new therapeutic strategies for RUNX1-altered leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.192773DOI Listing
February 2019

Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital;

Normal hematopoiesis can be disrupted by the leukemic bone marrow microenvironment, which leads to cytopenia-associated symptoms including anemia, hemorrhage and infection. Among them, thrombocytopenia is a major and fatal complication in patients with acute leukemia. However, the mechanisms underlying defective thrombopoiesis in leukemia have not been fully elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.214593DOI Listing
February 2019

Pretransplant HLA Typing Revealed Loss of Heterozygosity in the Major Histocompatibility Complex in a Patient with Acute Myeloid Leukemia.

Hum Immunol 2019 Feb 18. Epub 2019 Feb 18.

Indiana University School of Medicine, Department of Medicine, Division of Hematology and Oncology, Bone Marrow and Stem Cell Transplantation Program, Indiana University, Indianapolis, Indiana.

Introduction: Chromosomal abnormalities are frequent events in hematological malignancies. The degree of HLA compatibility between donor and recipient in hematopoietic stem cell transplantation is critical.

Purpose Of The Study: In this report, we describe an acute myeloid leukemia case with loss of heterozygosity (LOH) encompassing the entire HLA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humimm.2019.02.009DOI Listing
February 2019

Hyperammonemia From Ureaplasma Infection in an Immunocompromised Child.

J Pediatr Hematol Oncol 2019 Feb 15. Epub 2019 Feb 15.

Miller Children's and Women's Hospital Long Beach.

Idiopathic hyperammonemia is a rare, poorly understood, and often lethal condition that has been described in immunocompromised patients. This report describes an immunocompromised patient with acute myelogenous leukemia who developed persistent hyperammonemia up to 705 µmol/L (normal, 0 to 47 µmol/L) refractory to multiple different therapies. However, after beginning azithromycin and then doxycycline therapy for Ureaplasma species infection, the patient showed immediate and sustained clinical improvement and resolution of ammonia levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001414DOI Listing
February 2019

Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review.

Immunotherapy 2019 Apr;11(5):373-378

Department of Hematology, Taussig Cancer Center, Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.

Blinatumomab and donor lymphocyte infusion (DLI) combination is a promising cancer therapy, whereby blinatumomab might achieve an initial reduction in leukemic-cell burden using T cells, and after tumor clearance, DLI can potentially stimulate the donor immune system to achieve longer lasting remission. Here, we present a 51-year-old female with mixed phenotype acute leukemia who had a hematologic relapse 3 months after she received total body irradiation-based myeloablative allogeneic hematopoietic stem cell transplantation from an unrelated human leukocyte antigen matched (10/10) donor and achieved complete remission with minimal residual disease negativity by multi-parameter flow cytometry using the combination of blinatumomab and DLI. To the best of our knowledge, this is the first report to describe the use of blinatumomab and DLI combination therapy in the treatment of B/myeloid mixed phenotype acute leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0104DOI Listing

Pre-analytical parameters associated with unsuccessful karyotyping in myeloid neoplasm: a study of 421 samples.

Braz J Med Biol Res 2019 Feb 14;52(2):e8194. Epub 2019 Feb 14.

Hospital Israelita Albert Einstein, São Paulo, SP, Brasil.

Cytogenetics is essential in myeloid neoplasms (MN) and pre-analytical variables are important for karyotyping. We assessed the relationship between pre-analytical variables (time from collection to sample processing, material type, sample cellularity, and diagnosis) and failures of karyotyping. Bone marrow (BM, n=352) and peripheral blood (PB, n=69) samples were analyzed from acute myeloid leukemia (n=113), myelodysplastic syndromes (n=73), myelodysplastic syndromes/myeloproliferative neoplasms (n=17), myeloproliferative neoplasms (n=137), and other with conclusive diagnosis (n=6), and reactive disorders/no conclusive diagnosis (n=75). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1414-431X20188194DOI Listing
February 2019

Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.

Leuk Res 2019 Jan 24;79:6-16. Epub 2019 Jan 24.

Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China. Electronic address:

The BCR-ABL fusion gene (BCR-ABL) has different subtypes such as p210 and p190 with p190 appear to lead to a worse prognosis. To explore the mechanism of difference in pathogenesis and prognosis in different BCR-ABL subtype-related leukemia, expression profile microarray analysis was conducted between p190 and p210 patients and verified by RT-PCR. The p21-activated kinase (PAK1) gene was chosen and regulation of the PAK1-STAT5 biological axis and its influence on proliferation and apoptosis in leukemia cells were also analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.012DOI Listing
January 2019

Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia.

Oncotarget 2019 Jan 25;10(8):869-882. Epub 2019 Jan 25.

Pediatric Hematology/Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.

Nucleophosmin(NPM1)-mutated protein, a leukemia-specific antigen, represents an ideal target for AML immunotherapy. We investigated the dynamics of NPM1-mutated-specific T cells on PB and BM samples, collected from 31 adult -mutated AML patients throughout the disease course, and stimulated with mixtures of 18 short and long peptides (9-18mers), deriving from the complete C-terminal of the NPM1-mutated protein. Two 9-mer peptides, namely LAVEEVSLR and AVEEVSLRK (13. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26617DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368236PMC
January 2019

T-cell activity against AML improved by dual-targeted T cells stimulated through T-cell and IL7 receptors.

Cancer Immunol Res 2019 Feb 19. Epub 2019 Feb 19.

Pediatrics, University of Michigan-Ann Arbor

The development of engineered T cells to treat acute myeloid leukemia (AML) is challenging due to difficulty in target selection and the need for robust T-cell expansion and persistence. We designed a T cell stimulated to kill AML cells based on recognition of the AML-associated surface marker CLEC12A, via secretion of a CLEC12AxCD3 bispecific "engager" molecule (CLEC12A-ENG). CLEC12A-ENG T cells are specifically activated by CLEC12A, are not toxic to hematopoietic progenitor cells, and exhibit antigen-dependent AML killing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0748DOI Listing
February 2019

Infection of B Cell Follicle-Resident Cells by Friend Retrovirus Occurs during Acute Infection and Is Maintained during Viral Persistence.

MBio 2019 Feb 19;10(1). Epub 2019 Feb 19.

Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany

B cell follicles of the spleen and lymph nodes are immune privileged sites and serve as sanctuaries for infected CD4 cells in HIV infection. It is assumed that CD8 T cell responses promote the establishment of the reservoir, as B cell follicles do not permit CD8 T cell entry. Here we analyzed the infected cell population in the Friend retrovirus (FV) infection and investigated whether FV can similarly infect follicular cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/mBio.00004-19DOI Listing
February 2019

Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition.

Blood Adv 2019 Feb;3(4):552-563

The Leucegene Project at Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada.

Patients diagnosed with acute myeloid leukemia with complex karyotype (CK AML) have an adverse prognosis using current therapies, especially when accompanied by alterations. We hereby report the RNA-sequencing analysis of the 68 CK AML samples included in the Leucegene 415 patient cohort. We confirm the frequent occurrence of alterations in this subgroup and further characterize the allele expression profile and transcript alterations of this gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018028480DOI Listing
February 2019

The Enigmatic Protein Kinase C-eta.

Authors:
Alakananda Basu

Cancers (Basel) 2019 Feb 13;11(2). Epub 2019 Feb 13.

Department of Microbiology, Immunology & Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.

Protein kinase C (PKC), a multi-gene family, plays critical roles in signal transduction and cell regulation. Protein kinase C-eta (PKCη) is a unique member of the PKC family since its regulation is distinct from other PKC isozymes. PKCη was shown to regulate cell proliferation, differentiation and cell death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020214DOI Listing
February 2019

Upregulation of miR-504-3p is associated with favorable prognosis of acute myeloid leukemia and may serve as a tumor suppressor by targeting MTHFD2.

Eur Rev Med Pharmacol Sci 2019 Feb;23(3):1203-1213

Department of Hematology, Jining No. 1 People's Hospital, Jining City, Shandong Province, China.

Objective: Deregulated expression of miRNAs contributes to the development of acute myeloid leukemia (AML). miR-504-3p, one of these miRNAs, has been found have upregulated expression in various human malignancies. Our present study aimed to detect the expression of miR-504-3p and its biological effect in AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_201902_17013DOI Listing
February 2019

Correlation between IL-7 genomic protein methylation level and acute myeloid leukemia.

Authors:
Z-H Li Y Liu S-Y Gao

Eur Rev Med Pharmacol Sci 2019 Feb;23(3):1196-1202

Medicine Experimental Training Center, Weifang Medical University, Weifang, P. R. China.

Objective: To detect Interleukin-7 (IL-7) gene methylation status and transcription level in leukemia cells of peripheral blood of patients with Acute Myelocytic Leukemia (AML) and in the cell lines (HL-60, HL-60/ADM, SKM-1) of AML and myelodysplastic syndrome (MDS), and explore its relationship with the pathogenesis of AML.

Patients And Methods: A total of 55 AML patients (AML group) and 30 healthy adults (Healthy group) from June 2015 to June 2018 were enrolled in this study. The genomic DNA of leukemia cells in peripheral blood was extracted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_201902_17012DOI Listing
February 2019

Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium.

Cancer Epidemiol 2019 Feb 15;59:158-165. Epub 2019 Feb 15.

Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden. Electronic address:

Background: Parental age has been associated with several childhood cancers, albeit the evidence is still inconsistent.

Aim: To examine the associations of parental age at birth with acute myeloid leukemia (AML) among children aged 0-14 years using individual-level data from the Childhood Leukemia International Consortium (CLIC) and non-CLIC studies.

Material/methods: We analyzed data of 3182 incident AML cases and 8377 controls from 17 studies [seven registry-based case-control (RCC) studies and ten questionnaire-based case-control (QCC) studies]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canep.2019.01.022DOI Listing
February 2019
2.558 Impact Factor

Myeloablative single-unit cord blood transplantation overcomes the negative prognostic impact of FLT3-ITD in adult acute myeloid leukemia.

Leuk Lymphoma 2019 Feb 18:1-4. Epub 2019 Feb 18.

a Department of Hematology/Oncology , The Institute of Medical Science The University of Tokyo , Tokyo , Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1579325DOI Listing
February 2019

Health State Utilities Associated with Treatment Options for Acute Myeloid Leukemia (AML).

J Med Econ 2019 Feb 18. Epub 2019 Feb 18.

f Jazz Pharmaceuticals, Inc. , Palo Alto , CA , USA.

Aims Acute myeloid leukemia (AML) treatment typically involves remission induction chemotherapy followed by consolidation chemotherapy. New treatments for AML have recently been introduced, including a chemotherapy formulation called CPX-351, which is administered via less time-intensive IV infusion than the standard "7 + 3" continuous infusion regimen of cytarabine plus an anthracycline. The purpose of this study was to estimate utilities that could be used in economic modeling of AML treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1584108DOI Listing
February 2019

Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases.

Expert Opin Investig Drugs 2019 Feb 18. Epub 2019 Feb 18.

a Penn State Hershey Medical Center , 500 University Drive, Hershey , PA , 17033.

Introduction: Tyrosine kinases (TKs) drive cell survival and proliferation in many normal and malignant cell types. TKs are frequently mutated in acute myeloid leukemia (AML) and hence are increasingly targeted. The management of AML has dramatically improved because of TKI-targeted treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1584610DOI Listing
February 2019

A Myelodysplastic Syndrome with Concurrent Basophilia and Eosinophilia Lacking Oncogenic Mutations in 54 Relevant Genes.

Clin Lab 2019 Jan;65(1)

Myelodysplastic syndromes (MDS) with basophilia or eosinophilia are very rare and portend poor prognoses. We present a rare patient who had MDS with excess blasts as well as peripheral basophilia and concurrent bone marrow (BM) basophilia/eosinophilia. She had a complex karyotype including 5q and 7q deletions; however, no oncogenic mutations were observed on next-generation sequencing of 54 genes known to be frequently mutated in acute myeloid leukemia/MDS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2018.180729DOI Listing
January 2019

The Relationship between Fatigue and Cytokine Levels in Patients with Acute Myeloid Leukemia.

Int J Hematol Oncol Stem Cell Res 2018 Oct;12(4):318-321

Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Cancer-related fatigue (CRF) is a very prominent complaint and disabling symptom in cancer patients probably influenced by endogenous cytokines. But, the published data on this subject are limited. We explored the relationship of cytokines such as tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) with fatigue in patients with AML. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375377PMC
October 2018

Association between TLR2 and TLR4 Expression and Response to Induction Therapy in Acute Myeloid Leukemia Patients.

Int J Hematol Oncol Stem Cell Res 2018 Oct;12(4):303-312

Department of Operative Dentistry, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.

Toll-like receptors (TLRs) are a family of transmembrane pattern-recognition receptors that play a crucial role in the realization of innate and adaptive immune response. TLRs may play a role in tumor development and growth because of expression or up-regulation of functional TLRs in some tumors and tumor cell lines. The participation of TLRs in the pathogenesis of acute myeloid leukemia (AML) remains unspecified. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375370PMC
October 2018

Evaluation of the CD123 Expression and FLT3 Gene Mutations in Patients with Acute Myeloid Leukemia.

Iran J Pathol 2018 25;13(4):438-446. Epub 2018 Sep 25.

Dept. of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Background And Objective: Identification of cytogenetic and molecular changes plays an important role in acute myeloid leukemia (AML) patients. Thus, they are used in classification, prognosis and treatment of the disease. The CD123 expression and FLT3 gene mutations are also the variations that may assist in prognosis and treatment of patients with AML. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358557PMC
September 2018

Synergistic cytotoxicity of homoharringtonine and etoposide in acute myeloid leukemia cells involves disrupted antioxidant defense.

Cancer Manag Res 2019 22;11:1023-1032. Epub 2019 Jan 22.

Department of Hematology, Affiliated Hospital of Jining Medical University, Jining 272029, Shandong Province, China,

Background/aims: Cytotoxicity induced by reactive oxygen species (ROS) is critical for the effectiveness of chemotherapeutic drugs used in the treatment of acute myeloid leukemia (AML). This study aimed to investigate whether ROS contributes to cytotoxicity in AML cells when treated with homoharringtonine (HHT) and etoposide (ETP) in combination.

Methods: AML cell lines THP1 and HL60 and primary AML cells from patients were treated with HHT and ETP alone or in combination, and cell viability was determined by trypan blue exclusion test, and apoptosis was analyzed by annexin-V/propidium iodide double staining as well as Western blot for measuring expression of cleaved caspase-9 and cleaved caspase-3. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/synergistic-cytotoxicity-of-homoha
Publisher Site
http://dx.doi.org/10.2147/CMAR.S187597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349074PMC
January 2019
1 Read

microRNA-628 inhibits the proliferation of acute myeloid leukemia cells by directly targeting IGF-1R.

Onco Targets Ther 2019 29;12:907-919. Epub 2019 Jan 29.

Department of Hematology, Jingjiang People's Hospital, The Seventh Affiliated Hospital of Yangzhou University, Jiangsu 214500, P.R. China,

Background: A variety of microRNAs (miRNAs) are aberrantly expressed in acute myeloid leukemia (AML), and these dysregulated miRNAs perform crucial roles in tumorigenesis and progression of AML. miR-628-3p (miR-628), one of the miRNAs dysregulated in multiple types of human cancers, exerts antitumor roles in different cancer types. However, no specific study has explored the expression pattern and role of miR-628 in AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S192137DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357892PMC
January 2019
1 Read

Incidence of infections after therapy completion in children with acute lymphoblastic leukemia or acute myeloid leukemia: a systematic review of the literature.

Leuk Lymphoma 2019 Feb 18:1-11. Epub 2019 Feb 18.

a Division of Haematology/Oncology, Department of Paediatrics , The Hospital for Sick Children , Toronto , Canada.

Infections are a common complication of treatment for pediatric acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). Less is known about infections occurring after treatment. We performed a systematic review of the literature to assess the incidence of infections after therapy completion in children and young adults with ALL or AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1573369DOI Listing
February 2019

Obstetrical and newborn outcomes among women with acute leukemias in pregnancy: a population-based study.

J Matern Fetal Neonatal Med 2019 Feb 17:1-7. Epub 2019 Feb 17.

a Department of Obstetrics and Gynecology , Jewish General Hospital, McGill University , Montreal , Canada.

Purpose: Acute leukemias (ALs) are rare but aggressive malignancies. The goal of our study was to determine the incidence, obstetrical, and newborn outcomes of ALs in pregnancy.

Materials And Methods: We performed a retrospective population-based cohort study on all births reported in the Health-Care Cost and Utilization Project-Nationwide Inpatient Sample between 1999 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14767058.2019.1579188DOI Listing
February 2019

Oral rehabilitation in a patient with sclerotic-phenotype chronic graft versus host disease: a case report.

Quintessence Int 2019 ;50(3):208-213

Acute myeloid leukemia is a bone marrow malignancy in which blasts count increases by more than 20% in the bone marrow. Allogeneic hematopoietic stem cell transplantation (alloHCT) is a treatment option for these patients with high risk of graft versus host disease (GVHD) development. Chronic GVHD (cGVHD) often mimics a variety of autoimmune conditions such as systemic lupus erythematous or systemic sclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3290/j.qi.a41973DOI Listing
January 2019

Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity.

Cell Metab 2019 Feb 5. Epub 2019 Feb 5.

Department of Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, NC, USA. Electronic address:

Crosstalk between metabolic and survival pathways is critical for cellular homeostasis, but the connectivity between these processes remains poorly defined. We used loss-of-function CRISPR/Cas9 knockout screening to identify metabolic genes capable of influencing cellular commitment to apoptosis, using sensitization to the BCL-2 inhibitor ABT-199 in BCL-2-dependent acute myeloid leukemia (AML) cell lines as a proxy for apoptotic disposition. This analysis revealed metabolic pathways that specifically cooperate with BCL-2 to sustain survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmet.2019.01.011DOI Listing
February 2019

Results of endoscopic nasal surgery in the treatment of invasive fungal sinusitis in children with cancer and immunosuppression.

Acta Otorrinolaringol Esp 2019 Feb 14. Epub 2019 Feb 14.

Departamento de Otorrinolaringología, Centro Clínico de Cabeza y Cuello, Ciudad de Guatemala, Guatemala.

Background And Objective: to describe the results of the treatment of invasive fungal sinusitis with nasal endoscopic surgery in an immunocompromised paediatric oncological population.

Methods: retrospective study of all patients diagnosed with invasive fungal sinusitis operated in the National Paediatric Oncology Unit between 2012 and 2016. Data taken from their medical history included: epidemiological characteristics, oncological diagnosis, haematological data, symptoms, tomographic studies, surgical interventions, results of pathology and cultures, medications received, complications, evolution and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.otorri.2018.09.001DOI Listing
February 2019

Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.

Leuk Lymphoma 2019 Feb 18:1-9. Epub 2019 Feb 18.

a Peking University People's Hospital , Peking University Institute of Hematology , Beijing , China.

Acute myeloid leukemia (AML) patients with biallelic CEBPA (bi CEBPA) mutations are considered prognostically favorable, but 38-58% of them still relapse. Therefore, recognizing patients with a high risk of relapse is important. We retrospectively analyzed 83 bi CEBPA AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1576868DOI Listing
February 2019

Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myeloid leukemia after single cord blood transplantation.

Biol Blood Marrow Transplant 2019 Feb 13. Epub 2019 Feb 13.

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

The different effects of pre-engraftment syndrome (PES) and acute graft-versus-host disease (GVHD) on transplant outcomes after cord blood transplantation (CBT) are unclear. We retrospectively evaluated the impact of PES and acute GVHD on relapse and survival after single CBT for 138 adult patients with hematological malignancies in our institute between 2004 and 2016. Multivariate analysis demonstrated that development of grade III to IV acute GVHD, particularly gut or liver involvement of acute GVHD, significantly contributed to higher non-relapse mortality (P<0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.007DOI Listing
February 2019
1 Read

8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia.

J Cell Physiol 2019 Feb 15. Epub 2019 Feb 15.

Hematology Malignancies and Stem Cell Transplantation Institute, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California.

Nucleoside analogs represent the backbone of several distinct chemotherapy regimens for acute myeloid leukemia (AML) and combination with tyrosine kinase inhibitors has improved survival of AML patients, including those harboring the poor-risk FLT3-ITD mutation. Although these compounds are effective in killing proliferating blasts, they lack activity against quiescent leukemia stem cells (LSCs), which contributes to initial treatment refractoriness or subsequent disease relapse. The reagent 8-chloro-adenosine (8-Cl-Ado) is a ribose-containing, RNA-directed nucleoside analog that is incorporated into newly transcribed RNA rather than in DNA, causing inhibition of RNA transcription. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcp.28294
Publisher Site
http://dx.doi.org/10.1002/jcp.28294DOI Listing
February 2019
2 Reads

Prevalence of deaths in a cohort of girls and women with cryopreserved ovarian tissue.

Acta Obstet Gynecol Scand 2019 Feb 15. Epub 2019 Feb 15.

The Fertility Clinic, section 4071, University Hospital of Copenhagen Rigshospitalet, Copenhagen, Denmark.

Introduction: Ovarian tissue cryopreservation (OTC) is increasingly offered to women in need of fertility preservation. However, little is known about the risk of these women dying before they use the preserved material.

Material And Methods: From 1999 to 2016, 927 girls and women underwent OTC in our center, prior to receiving gonadotoxic treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.13576DOI Listing
February 2019
1 Read

Adding Oral Pioglitazone to Standard Induction Chemotherapy of Acute Myeloid Leukemia: A Randomized Clinical Trial.

Clin Lymphoma Myeloma Leuk 2019 Jan 19. Epub 2019 Jan 19.

Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Background: The hypothesis of an effect by thiazolidinedione on leukemia cells was proposed 2 decades ago, but there is little clinical evidence regarding its efficacy. We evaluated the safety and efficacy of adding pioglitazone to standard induction chemotherapy in patients with acute myeloid leukemia (AML).

Patients And Methods: In this randomized clinical trial, newly diagnosed AML patients were randomized to 1 of 2 groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.01.006DOI Listing
January 2019

Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia.

Cancers (Basel) 2019 Feb 14;11(2). Epub 2019 Feb 14.

Division of Hematology, Spedali Civili, 25123 Brescia, Italy.

Considerable progress has been made in the treatment of acute myeloid leukemia (AML). However, current therapeutic results are still unsatisfactory in untreated high-risk patients and poorer in those with primary refractory or relapsed disease. In older patients, reluctance by clinicians to treat unfit patients, higher AML cell resistance related to more frequent adverse karyotype and/or precedent myelodysplastic syndrome, and preferential involvement of chemorefractory early hemopoietic precursors in the pathogenesis of the disease further account for poor prognosis, with median survival lower than six months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020224DOI Listing
February 2019
1 Read

Exploiting Protein Corona around Gold Nanoparticles Conjugated to p53 Activating Peptide to Increase the Level of Stable p53 Proteins in Cells.

Bioconjug Chem 2019 Feb 15. Epub 2019 Feb 15.

Therapeutic peptides suffer from major drawbacks such as peptide degradation in vivo due to proteolysis. Gold nanoparticles (AuNPs) are an effective carrier for therapeutic peptides that improve their stability in vivo, while also enabling non-specific adsorption of complementary proteins to enhance their effectiveness. Using p53 peptide as a model known to disrupt the intracellular MDM2-p53 protein-protein interaction which tags the endogenous p53 proteins for degradation, we conjugated p53 peptides to AuNPs (AuNP-p53) and examined the functionality of AuNP-p53 to release the endogenous p53 proteins from being tagged for degradation, thereby increasing the level of stable p53 proteins in acute myeloid leukemia 2 (AML2) cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.bioconjchem.9b00032DOI Listing
February 2019
1 Read

[Diagnosis and treatment of acute myeloid leukemia : The updated 2018 Onkopedia Guideline].

Internist (Berl) 2019 Feb 14. Epub 2019 Feb 14.

Medizinische Klinik und Poliklinik I, Universitätsklinikum TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.

In April 2018, an updated version of the previously published guidelines on acute myeloid leukemia (AML) from 2010 and 2017 was released. A revision was necessary because of two positive aspects: First, new data and insights on risk stratification and monitoring, and second, the clinical development and approval of new agents. The modified genetic risk classification allows a more precise distinction of different diagnostic groups and consequently a better matched post-remission treatment. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00108-019-0562-2
Publisher Site
http://dx.doi.org/10.1007/s00108-019-0562-2DOI Listing
February 2019
2 Reads

Breast cancer resistance protein (BCRP) gene expression in a cohort of adult Egyptian patients with acute myeloid leukemia.

Afr Health Sci 2018 Dec;18(4):958-964

Department of Clinical and Chemical Pathology, National Cancer Institute, Cairo University, Egypt.

Background: Acute myeloid leukemia (AML), an aggressive clonal disease, is genetically heterozygous. The prognostic role of expression of Breast Cancer Resistance Protein (BCRP) gene, which behaves as a multidrug transporter, in adult AML is ambiguous.

Objective: The objective is to assess the level of mRNA expression of BCRP gene in newly diagnosed cytogenetically normal adult Egyptian AML patients; and to clarify its potential influence and association between therapeutic responsiveness and disease free survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4314/ahs.v18i4.15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354849PMC
December 2018
1 Read

Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Sci Rep 2019 Feb 14;9(1):2046. Epub 2019 Feb 14.

Department of Hematology, Stem Cell Transplantation Unit, University of Health Sciences,Ankara Oncology Training and Research Hospital, Ankara, Turkey.

Post-transplant cyclophosphamide has become a promising medical option after allogeneic HSCT. In this study we aimed to evaluate the efficacy of cyclophosphamide and cyclosporine combination in acute and chronic graft-versus-host disease (GvHD) prophylaxis in acute myeloid leukemia (AML) cases scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Retrospective analysis of data from 40 cases who underwent allogeneic HSCT under GvHD prophylaxis with cyclophosphamide and cyclosporine combination between April 2016 and August 2017 was made. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-019-38644-1
Publisher Site
http://dx.doi.org/10.1038/s41598-019-38644-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376163PMC
February 2019
3 Reads

SHP1 and SHP2 inhibition enhances the pro-differentiative effect of phorbol esters: an alternative approach against acute myeloid leukemia.

J Exp Clin Cancer Res 2019 Feb 14;38(1):80. Epub 2019 Feb 14.

Department of Biochemistry and Molecular Biology, University of Salamanca, Edificio Departamental, Lab 122, Plaza Doctores de la Reina, S/N, P.O. 37007, Salamanca, Spain.

Background: The differentiation-based therapy for acute promyelocytic leukemia (APL) is an inspiring example for the search of novel strategies aimed at treatment of other subtypes of acute myeloid leukemia (AML). Thus, the discovery of new molecular players in cell differentiation becomes a paramount research area to achieve this goal. Here, the involvement of the protein tyrosine phosphatases SHP1 and SHP2 on leukemic cells differentiation is shown, along with the therapeutic possibilities of their targeting to enhance the differentiation induction effect of phorbol esters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1097-zDOI Listing
February 2019
1 Read

Investigation of phytochemical constituents of anti-leukemic herbal drugs used by the traditional healers of Purulia, Birbhum and Bankura districts of West Bengal.

Nat Prod Res 2019 Feb 15:1-6. Epub 2019 Feb 15.

b Medicinal Chemistry and Immunology Lab (ASK-II-406) School of Chemical and Biotechnology , SASTRA Deemed to Be University , Thanjavur , Tamilnadu , India.

In the present work, 16 different plant drugs used by traditional healers from West Bengal were screened through in vitro cell line model. Herbal drugs used by traditional tribal healers in Purulia, Birbhum and Bankura districts of West Bengal were collected and screening against acute myeloid leukemia (AML) cell line (HL-60). Among 16 plant extracts, bark of Flacourtia indica (66. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14786419.2019.1566818DOI Listing
February 2019
1 Read